PMID- 33314317
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20211104
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 35
IP  - 3
DP  - 2021 Mar
TI  - The relationship between plasma serglycin levels and the diagnosis of diabetic 
      retinopathy.
PG  - e23663
LID - 10.1002/jcla.23663 [doi]
LID - e23663
AB  - BACKGROUND: Diabetic retinopathy (DR), a microvascular complication which is 
      closely related to diabetes, remains the leading cause of vision loss around the 
      world among older adults. Serglycin (SRGN) was known as a hematopoietic cell 
      granule proteoglycan, exerting its function in the formation of mast cell 
      secretory granules and mediates the storage of various compounds in secretory 
      vesicles. The present study illustrates the potential clinical value and 
      experimental mechanisms of SRGN in the DR. METHODS: Firstly, the mRNA expression 
      and protein expression of SRGN in plasma samples from NPDR, PDR patients, type 2 
      diabetes mellitus (T2Dm) cases, and healthy controls were measured by qPCR and 
      Western blotting assays, respectively. Then, the potentials of SRGN functioning 
      as a diagnostic indicator in DR were verified by the receiver operating 
      characteristic (ROC) analysis. We established in vitro DR model of human retinal 
      endothelial cells through high-glucose treatment. The expression of SRGN and its 
      mechanisms of regulating cellular processes were illustrated subsequently. 
      RESULTS: Our data revealed that SRGN was dramatically upregulated in NPDR and PDR 
      cases compared with healthy controls and T2DM patients; meanwhile, the expression 
      of SRGN was further increased in the PDR group with regard to the NPDR group. 
      Furthermore, the ROC analysis demonstrated that SRGN could distinguish the DR 
      cases from type 2 diabetes mellitus (T2DM) patients and healthy controls with the 
      area under the curve (AUC) of 0.7680 (95% CI = 0.6780 ~ 0.8576, 
      sensitivity = 47.27%, specificity = 100%, cutoff value = 1.4727) and 0.8753 (95% 
      CI = 0.8261 ~ 0.9244, sensitivity = 69.23%, specificity = 100%, cutoff 
      value = 1.6923), respectively. In vitro high-glucose treatment showed that the 
      SRGN expressions were dramatically increased. The loss of SRGN could partially 
      counteract the inhibition of HREC proliferation caused by high-glucose 
      stimulation. Meanwhile, SRGN knockdown could reverse the promotion of HREC 
      apoptosis induced by high glucose as well. CONCLUSIONS: Consequently, our study 
      implied that SRGN might serve as a promising biomarker with high specificity and 
      sensitivity in the DR diagnosis and progression.
CI  - (c) 2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley 
      Periodicals LLC.
FAU - Wang, Layi
AU  - Wang L
AUID- ORCID: 0000-0001-6497-5411
AD  - Ningbo Eye Hospital, Ningbo, China.
FAU - Han, Yin
AU  - Han Y
AUID- ORCID: 0000-0002-1702-643X
AD  - Ningbo Eye Hospital, Ningbo, China.
FAU - Wang, Xiajun
AU  - Wang X
AUID- ORCID: 0000-0002-2043-4418
AD  - Ningbo Eye Hospital, Ningbo, China.
LA  - eng
PT  - Journal Article
DEP - 20201212
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Proteoglycans)
RN  - 0 (Vesicular Transport Proteins)
RN  - 0 (serglycin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Apoptosis/genetics
MH  - Case-Control Studies
MH  - Cell Line
MH  - Cell Proliferation/drug effects/genetics
MH  - Diabetes Mellitus, Type 2/blood
MH  - Diabetic Retinopathy/*blood/diagnosis
MH  - Female
MH  - Glucose/pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proteoglycans/*blood/genetics
MH  - Retinal Pigment Epithelium/cytology/drug effects
MH  - Vesicular Transport Proteins/*blood/genetics
PMC - PMC7957973
OTO - NOTNLM
OT  - SRGN
OT  - biomarker
OT  - diabetic retinopathy
OT  - diagnosis
COIS- None.
EDAT- 2020/12/15 06:00
MHDA- 2021/11/05 06:00
PMCR- 2020/12/12
CRDT- 2020/12/14 11:09
PHST- 2020/11/04 00:00 [revised]
PHST- 2020/10/10 00:00 [received]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
PHST- 2020/12/14 11:09 [entrez]
PHST- 2020/12/12 00:00 [pmc-release]
AID - JCLA23663 [pii]
AID - 10.1002/jcla.23663 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2021 Mar;35(3):e23663. doi: 10.1002/jcla.23663. Epub 2020 Dec 
      12.